Listen to “Women diagnosed with a certain type of breast cancer face a vastly different outlook than others with the disease.” on Spreaker.
While the five-year survival rate for breast cancer has reached 90-percent in recent years, for women with metastatic breast cancer — where the cancer has spread to other parts of the body — that rate is only 28-percent. And when COVID-19 caused delays in routine mammograms, doctors saw a jump in these advanced cases. Here now to talk about the latest developments and why breast cancer awareness needs to happen year-round, is Dr. Ramaswamy (RAH-muh-swah-mee) from The Ohio State University Medical Center.
What should people be aware of in terms of breast cancer screening and COVID-19?
Can you tell us about your experience treating people diagnosed with MBC? What are the biggest unmet needs and how is the treatment landscape changing?
What are some of the major challenges in MBC today?
Why is it so important for women to not delay routine mammogram screenings?
Where can the MBC community go for more information and support?
BIO-Dr. Bhuvana Ramaswamy is a breast cancer oncologist, physician-scientist at the James. She leads the breast medical oncology section and is also the Chair of the Clinical Scientific Review Committee for the James. Her research interests are in drug-resistance and racial disparities in cancer outcomes. Her lab focuses on finding the molecular link between breastfeeding and risk of breast cancer. She was named as one the “top 27 breast medical oncologists” in the nation by Forbes in 2017 and recently received the Mazzaferri-Ellison Society of Master Clinicians Award.
Interview is Courtesy: Seagen
#breast #cancer #disease #metastatic #covid #mammograms #doctors #ramaswarmy #treating #diagnosed #mbc #treatment #screening #community #support #bhuvana #oncologist #drug #scientist #seagen